Technology Diffusion, Health Outcomes, and Healthcare Expenditures

Dartmouth College, Hanover NH

Investigators

Linked publications & trials

Abstract

DESCRIPTION: In previous research wide variations have been found in both healthcare spending and in health outcomes, with little correlation between the two. These studies were limited to cross-sectional analysis, and tell little about the dynamic process by which these patterns arise. One hypothesis is that variation across regions in rates of technology diffusion, whether for highly effective treatments (with a large impact on health outcomes) or for expensive treatments with unknown value (with a large impact on expenditures), can explain the observed cross-sectional patterns of spending and outcomes. In this proposal, Aim 1 seeks to better understand the diffusion of highly effective healthcare such as hemoglobin A1C (HbA1c) tests for blood glucose control among diabetic patients. Using the national Doximity database on every physician in the U.S., along with information about physician-hospital networks (PHN) and physician social networks, the research team will test why HbA1c diffused so rapidly (and among all racial and ethnic groups) in some areas but not others. They will also test whether more rapid diffusion of HbA1c reduced rates of neuropathy, retinopathy, and amputation. Aim 2 focuses on the diffusion of generally beneficial treatments but where the treatment can actually harm specific types of patients. Two examples are considered: the rapid growth in implantable cardioverter defibrillators (ICDs), and the growth in new and expensive anticoagulants - dabigatran, apixaban and rivaroxaban. Aim 3 studies the opposite of diffusion - exnovation or a retreat from use - to ask how physician-hospital networks and regions scaled back on treatments newly found to have poor value for subgroups of patients. The proposal considers two specific treatments: the sharp reduction in carotid endarterectomy (both surgery and stents), and the decline in the use of Rosiglitazone (Avandia), an anti-diabetic drug, following a 2007 publication demonstrating serious cardiovascular risks. In these cases, the most effective exnovation patterns should experience the largest drop in use for the less appropriate patients. Aim 4 examines the diffusion of treatments with unknown or even adverse consequences, such as the rapid growth in some regions (but not others) in ICU bed capacity. The research team will study the network and diffusion patterns for extramedical treatments - illegal behavior motivated by profit and with no benefit for patients, with one example being the rise and fall of immunoglobulin infusions in 2002-2005. Finally, the research group will use results from these four aims to return to the central hypothesis: can observed differences in treatment-specific diffusion explain observed patterns in regional variations in health outcomes and spending?